Website stats for Allogene - allogene.com
Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy. We start with T cells from healthy donors to allow for the creation of off-the-shelf...
allogene.com was registered 2 decades 1 year ago. It has a alexa rank of #906,887 in the world. It is a domain having .com extension. It is estimated worth of $ 1,440.00 and have a daily income of around $ 6.00. As no active threats were reported recently, allogene.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 967 |
| Daily Pageviews: | 1,934 |
Estimated Valuation
| Income Per Day: | $ 6.00 |
| Estimated Worth: | $ 1,440.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 906,887 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
99.83.217.73
Hosted Country:
US
Location Latitude:
47.6062Location Longitude:
-122.332Search Engine Results For allogene.com
Allogene Therapeutics - Crunchbase Company Profile & Funding
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics Email Format | allogene.com Emails
Allogene Therapeutics uses 2 email formats: 1. first '.' [email protected] (98.0%) . Enter a name to find & verify an email >>>
Allogene Therapeutics Information | Allogene Therapeutics Profile
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic ...
Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote ...
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the ...
Allogene Therapeutics - Biocom California
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical- stage biotechnology company pioneering the development of allogeneic chimeric ...
Allogene Therapeutics Inc - Company Profile and News - Bloomberg ...
Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment ...
Allogene Therapeutics Email Formats & Employee Phones ...
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) ...
Allogene Therapeutics Reports First Quarter 2021 Financial
May 5, 2021 ... Allogene Therapeutics, with headquarters in South San Francisco, is a clinical- stage biotechnology company pioneering the development of ...
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA ...
Jun 5, 2019 ... Allogene Therapeutics, Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA. Electronic address: [email protected]. 2 ...
Allogene Therapeutics: Allogeneic Cell Therapy
Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is ...
Allogene Therapeutics Announces Participation in ... - MarketWatch
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences. Published: May 20, 2021 at 8:30 a.m. ET. Comments ...
Allogene Therapeutics | LinkedIn
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) ...
Allogene Therapeutics Inc (ALLO : NASDAQ) Stock Price & News ...
Get the latest Allogene Therapeutics Inc (ALLO) real-time quote, historical performance, charts, and other financial information to help you make more informed ...
Allogene Therapeutics Inc (ALLO) Quote - XNAS | Morningstar
Allogene Therapeutics Inc is a United States-based clinical stage immuno- oncology company. It is mainly engaged in the development and commercialization of ...
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
May 12, 2021 ... Webinar Scheduled for 2:30 PM PT/5:30 PM ET. SOUTH SAN FRANCISCO, Calif ., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene ...
Allogene Therapeutics, Inc. (ALLO) Stock Price Today, Quote ...
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the ...
Allogene Therapeutics Inc. Company Profile - The Business Journals
Allogene Therapeutics Inc. South San Francisco, CA. Overview. Industry: Biotechnology; Employees: 70 [2]
ALLO - Allogene Therapeutics Inc. • BioPharmCatalyst
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company ...
ALLO - Allogene Therapeutics Inc Company Profile - CNNMoney.com
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically ...
Allogene Therapeutics Company Profile: Stock Performance ...
Information on stock, financials, earnings, subsidiaries, investors, and executives for Allogene Therapeutics. Use the PitchBook Platform to explore the full ...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | 1 | H2 Headings: | 4 |
| H3 Headings: | Not Applicable | H4 Headings: | 6 |
| H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
| Total IFRAMEs: | Not Applicable | Total Images: | 16 |
| Google Adsense: | Not Applicable | Google Analytics: | UA-116766960-1 |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| AlloCAR T™ | 9 | 1.59 % | No |
| CELL THERAPY | 5 | 0.883 % | No |
| T™ THERAPY | 4 | 0.707 % | No |
| Releases Events | 4 | 0.707 % | No |
| Press Releases | 4 | 0.707 % | No |
| CAR T | 4 | 0.707 % | No |
| Allogene is | 3 | 0.53 % | No |
| T™ therapy | 3 | 0.53 % | No |
| to treat | 3 | 0.53 % | No |
| Our Tweets | 2 | 0.353 % | No |
| Tweets Media | 2 | 0.353 % | No |
| Community Guidelines | 2 | 0.353 % | No |
| Media Resources | 2 | 0.353 % | No |
| Resources Community | 2 | 0.353 % | No |
| To Know | 2 | 0.353 % | No |
| CENTER Press | 2 | 0.353 % | No |
| NEWS CENTER | 2 | 0.353 % | No |
| Exhibit NEWS | 2 | 0.353 % | No |
| Events Perspectives | 2 | 0.353 % | No |
| Perspectives Get | 2 | 0.353 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| NEWS CENTER Press Releases | 2 | 0.353 % | No |
| Exhibit NEWS CENTER Press | 2 | 0.353 % | No |
| CENTER Press Releases Events | 2 | 0.353 % | No |
| Releases Events Perspectives Get | 2 | 0.353 % | No |
| Events Perspectives Get To | 2 | 0.353 % | No |
| Virtual Exhibit NEWS CENTER | 2 | 0.353 % | No |
| Publications Virtual Exhibit NEWS | 2 | 0.353 % | No |
| Trials Expanded Access Scientific | 2 | 0.353 % | No |
| Clinical Trials Expanded Access | 2 | 0.353 % | No |
| Expanded Access Scientific Publications | 2 | 0.353 % | No |
| Access Scientific Publications Virtual | 2 | 0.353 % | No |
| Scientific Publications Virtual Exhibit | 2 | 0.353 % | No |
| Perspectives Get To Know | 2 | 0.353 % | No |
| Get To Know Us | 2 | 0.353 % | No |
| Releases Events Presentations Stock | 2 | 0.353 % | No |
| Press Releases Events Presentations | 2 | 0.353 % | No |
| Events Presentations Stock Information | 2 | 0.353 % | No |
| to treat all eligible | 2 | 0.353 % | No |
| treat all eligible patients | 2 | 0.353 % | No |
| Resources Community Guidelines INVESTORS | 2 | 0.353 % | No |
HTTP Header Analysis
Status-Code: 200
Status: 200
Date: Tue, 20 Apr 2021 17:05:20 GMT
Content-Type: text/html;charset=UTF-8
Transfer-Encoding: chunked
Connection: keep-alive
Server: nginx/1.14.0 (Ubuntu)
Vary: Accept-Encoding
Content-Language: en
X-Frame-Options: SAMEORIGIN
Content-Encoding: gzip
Domain Information
| Domain Registrar: |
GoDaddy.com, LLC
|
|---|---|
| Registration Date: | 2002-12-03 2 decades 1 year 11 months ago |
| Last Modified: | 2020-06-06 4 years 5 months 2 weeks ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| ns23.domaincontrol.com | |
97.74.101.12 | United States |
| ns24.domaincontrol.com | |
173.201.69.12 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| allogene.com | A | 1796 |
IP: 75.2.88.49 |
| allogene.com | A | 1796 |
IP: 99.83.217.73 |
| allogene.com | NS | 3600 |
Target: ns23.domaincontrol.com |
| allogene.com | NS | 3600 |
Target: ns24.domaincontrol.com |
| allogene.com | SOA | 3600 |
MNAME: ns23.domaincontrol.com RNAME: dns.jomax.net Serial: 2021041514 Refresh: 28800 Retry: 7200 Expire: 604800 |
| allogene.com | MX | 1800 |
Priority: 10 Target: cluster9.us.messagelabs.com |
| allogene.com | MX | 1800 |
Priority: 20 Target: cluster9a.us.messagelabs.com |
| allogene.com | TXT | 1800 |
TXT: smartsheet-site-validation=smNhNJAIW5Pzj DuSi7DWp6MoofuYEYw2 |
| allogene.com | TXT | 1800 |
TXT: adobe-idp-site-verification=efd0f9d54970 4a6347956b5e32267792050a3b7176e884de09e5 e401b9924e5d |
| allogene.com | TXT | 1800 |
TXT: ZOOM_verify_zG2QDLoBSiGzATfQumvSmw |
| allogene.com | TXT | 1800 |
TXT: google-site-verification=JiZc4SLa1mIhFfv Iu40-7FYa9Gv1bcNQ_flXLB46d5o |
| allogene.com | TXT | 1800 |
TXT: MS=ms69995567 |
| allogene.com | TXT | 1800 |
TXT: cisco-ci-domain-verification=1faaaa2f769 04efcc32fa55a4fa51b5a5d153208b74d52709c5 449cb3c67907f |
| allogene.com | TXT | 1800 |
TXT: v=spf1 exists:%{i}._i.%{d}._d.espf.agari.com include:%{d}.7d.spf-protect.agari.com ~all |
| allogene.com | TXT | 1800 |
TXT: adobe-sign-verification=fe83651d96e78e4e b829c16324ad4606 |
| allogene.com | TXT | 1800 |
TXT: atlassian-domain-verification=d379NBNLTd zVTMmXgQDzvgnatcOHd4jWkTzbWAqDQwWQ7Z7xi2 YAd0EkhVBjPhpu |
Full WHOIS Lookup
Registry Domain ID:
92748722_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.godaddy.com
Registrar URL:
http://www.godaddy.com
Updated Date:
2020-06-05T23:37:26Z
Creation Date:
2002-12-02T19:36:14Z
Registry Expiry Date:
2026-12-02T19:36:14Z
Registrar: GoDaddy.com, LLC
Registrar
IANA ID: 146
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
480-624-2505
Domain Status: clientDeleteProhibited
https://icann.org/epp#clientDeleteProhibited
Domain Status:
clientRenewProhibited
https://icann.org/epp#clientRenewProhibited
Domain Status:
clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Domain Status:
clientUpdateProhibited
https://icann.org/epp#clientUpdateProhibited
Name Server:
NS23.DOMAINCONTROL.COM
Name Server:
NS24.DOMAINCONTROL.COM
DNSSEC: unsigned
URL of the ICANN Whois
Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last
update of whois database: 2021-04-20T17:05:04Z
Similarly Ranked Websites
Prepper Website | Preparedness • Survival • Alternative News
Prepper Website is the place where you can find the best of preparedness, homesteading, bushcraft and survival articles, videos and podcasts for preppers.
906,893 
$ 1,440.00
The Wiert Corner – irregular stream of stuff
Jeroen W. Pluimers on .NET, C#, Delphi, databases, and personal interests
906,896 $ 1,440.00
Training, eLearning, and Awesome Books - IconLogic
Adobe Captivate, RoboHelp, and FrameMaker. Articulate Storyline and TechSmith Camtasia training courses, step-by-step workbooks, and courseware development that utilizes skills...
906,897 $ 1,440.00
Η Νο1 Σχολή για Πιστοποιημένες Σπουδές | Σεμινάρια - Εξειδίκευση -...
Το Universal Training, Κέντρο δια βίου Μάθησης 2, υλοποιεί υψηλού επιπέδου σπουδές με καινοτόμα εκπαιδευτικά προγράμματα επαγγελματικής κατάρτισης και εξειδίκευσης σε τομείς...
906,901 $ 1,440.00